Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
ABC, adenosine-triphosphate–binding cassette; ALP, alkaline phosphatase; BF, bezafibrate; CYP, cytochrome P450; FDA, U.S. Food and Drug Administration; FF, fenofibrate; FXR, farnesoid X receptor; LXR, liver X receptor; mRNA, messenger RNA; PBC, primary biliary cirrhosis; PPAR, peroxisome proliferator-activated receptor; PSC, primary sclerosing cholangitis; PXR, pregnane X receptor; TGs, triglycerides; UDCA, ursodeoxycholic acid. In 1993, the effects of fibrates in lowering serum alkaline phosphatase (ALP) was shown for bezafibrate (BF) to be the result of hepatic, rather than bone or intestinal, isoenzymes.1 These initial observations led to the suggestion that fibrates might be beneficial for patients with an elevated ALP and cholestatic liver disease. Since then, several dozen case reports and pilot studies have demonstrated the efficacy of fibrates in reducing serum biomarkers of cholestasis and liver function abnormalities in patients with primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC) and incomplete responses to ursodeoxycholic acid (UDCA) monotherapy (Tables 1 and 2). Yet, despite the growing number of these observational studies, the mechanism(s) by which fibrates reduce biochemical markers of cholestasis, and whether fibrate therapy improves survival in these disorders, remains unclear. The study of Honda et al.2 in the current issue of HEPATOLOGY seeks to address the first of these issues. Their findings confirm that adjunct therapy with BF reduces ALP levels in adult patients with PBC who experienced an incomplete response to UDCA, and they further suggest that BF acts as a dual peroxisome proliferator-activated receptor (PPAR) and pregnane X receptor (PXR) agonist. These results are of interest, because fibrates are attracting increased attention as adjunct therapy for chronic cholestatic liver diseases. Nevertheless, this study raises several questions regarding the appropriate patient population for this therapy, the dosage of UDCA, as well as which fibrate to use, because BF is not U.S. Food and Drug Administration (FDA) approved. BF is a fibric-acid derivative and clinically used as a hypolipidemic agent to lower serum triglyceride (TG) levels, primarily through PPAR activation. Often, it has been referred to as a "PPAR-α" agonist; however, BF activates all three isoforms of human PPAR, specifically PPAR-α, PPAR-δ, and PPAR-γ, at similar concentrations (i.e., 50, 20, and 60 μM, respectively).3 Thus, the term "pan-PPAR" agonist is a more-accurate descriptive. In the United States, fenofibrate (FF) and gemfibrozil, PPAR-α-selective agonists, are the fibric-acid derivatives that are FDA approved and clinically used for treatment of hyperlipidemia. Recently, pilot studies in patients with PBC refractory to UDCA monotherapy demonstrated that FF also reduced biochemical features and symptoms of cholestasis.4-9 Honda et al. currently report the effects and assess the mechanisms of adjunct BF as an anticholestatic agent in 19 adults with early-stage PBC and compare their response to UDCA (600 and 10-13 mg/kg/day) monotherapy. Three months of combination therapy with BF (400 mg/day) led to a significant reduction in serum biliary enzymes, cholesterol, and TGs as well as modulation of PPAR-α and PXR target genes, including an up-regulation of the adenosine-triphosphate–binding cassette subfamily G transporters, ABCG5 and ABCG8. Although BF improved biochemical tests, the dose of UDCA was only 10-13 mg/kg/day and thus would be considered subtherapeutic. A recent study proposes that candidates requiring new therapeutic approaches should be limited to patients with ALP >1.5 times the upper limit of normal only after incompletely responding to optimal doses of UDCA of 13-15 mg/kg/day.10 Based on these criteria, it is possible that an increase of UDCA to 15 mg/kg/day might have provided adequate therapy in this particular patient cohort, particularly because the histological stage of fibrosis was only 1-2. Nevertheless, combination therapy improved biochemical manifestations of cholestasis in these patients. To explain possible mechanisms by which BF works, Honda et al. treated DPX2 cells, a derivative of the HepG2 cell line, which expresses PXR, with BF and compared the response to cells treated with rifampicin, a PXR agonist. High-dose BF (200 μM) activated PXR; however, GW4064 (3-30 μM), a farnesoid X receptor (FXR) agonist, also increased PXR activity similar to, if not greater than, BF, suggesting FXR involvement in PXR regulation. It is noteworthy that BF at 10 μM, which corresponds to plasma concentration of 400 mg/day in these patients, did not activate PXR. Thus, the conclusion that BF is a dual PPAR and PXR agonist, which is based on cytochrome P450 (CYP)3A4 messenger RNA (mRNA) and activity data at supratherapeutic doses, requires more study. Moreover, the possibility of coordinated regulation of PXR by PPAR isoforms as well as by FXR and the liver X receptor (LXR) should
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“, 50, 20, and 60 lM, respectively).(3) Thus, the term ‘‘pan-PPAR’’ agonist is a more-accurate descriptive.”
Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186 · cited 1×
“Levy et al.(6) 160 mg 13-15 mg/kg 20, 20 (PBC) Heartburn (n 1⁄4 2): study withdrawal ; ALP, IgM, AST, TGs, and serum cytokines Han et al.”
BackgroundIwasaki, S., Ohira, H., Nishiguchi, S., Zeniya, M., Kaneko, S., Onji, M., Ishibashi, H., Sakaida, I., Kuriyama, S., Ichida, T., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00305.x · Cited by 145
Bezafibrate treatment: a new medical approach for PBC patients?
Kanda, T., Yokosuka, O., Imazeki, F., & Saisho, H. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-002-1102-7 · Cited by 129 · cited 1×
“400 mg 600 mg 13, 10 (PBC) No side effects ; ALP, c-GTP, and IgM Kanda et al.(19) 400 mg 600 mg 11, 11 (PBC) Polydipsia (n 1⁄4 1),”
Cited by
Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317
Self-citationJones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30246-7 · Cited by 191
Cheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13465 · Cited by 139
Ghonem, N. S., Auclair, A. M., Hemme, C. L., Gallucci, G. M., de la Rosa Rodriguez, R., Boyer, J. L., & Assis, D. N. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1930 · Cited by 57
Self-citationFibrate treatment for primary biliary cirrhosis
Cuperus, F. J. C., Halilbasic, E., & Trauner, M. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000056 · Cited by 36
Metadata
- Authors
- Ghonem, N. S., & Boyer, J. L.
- Venue
- Hepatology
- Published
- 2013-05
- Volume
- 57
- Issue
- 5
- Pages
- 1691-1693
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1973298751
- Cited by
- 38
- References
- 4
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.